| Bioactivity | mono-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity[1]. |
| Invitro | Delivery of Mcl-1-specific anticancer siRNA (siMcl-1) using nanoparticles of mono-Pal-MTO and di-Pal-MTO (md11-Pal-MTO) in a 1:1 molar ratio enhances in vitro antitumour activity, reducing tumour cell viability by 81% and tumour size by 83%. Lipofectamine 2000-mediated transfection with siMcl-1 reduces tumour cell viability by 68%[1]. |
| Name | mono-Pal-MTO |
| CAS | 1349197-89-2 |
| Formula | C38H56N4O7 |
| Molar Mass | 680.87 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rae Sung Chang, et al. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials. 2011 Dec;32(36):9785-95. |
mono-Pal-MTO
CAS: 1349197-89-2 F: C38H56N4O7 W: 680.87
mono-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic ac
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.